Amunix Operating Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Amunix Operating Inc (Amunix) is a biotechnology company that offers therapeutic solutions. The company discovers and develops protein and peptide therapeutics. It uses its proprietary technology platform XTEN, a proprietary recombinant polypeptide that consists of naturally-occurring hydrophilic amino acids and is biodegradable, for the development of its products. Amunixs product pipeline includes VRS-317, NB1001, NB1002, AMX-342, AMX-182 and AMX-168. The company has developed technology based on XTEN, a hydrophilic polymer comprised of natural amino acids that can be attached to therapeutic peptides, proteins and small molecules. It provides products in the treatment areas include hemophilia, diabetes, short bowel syndrome, NASH, Oncology and lipodystrophy. The company operates through academic, biotechnology and pharmaceutical groups. Amunix is headquartered in Mountain View, California, the US.
Amunix Operating Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Amunix Operating Inc (Amunix) is a biotechnology company that offers therapeutic solutions. The company discovers and develops protein and peptide therapeutics. It uses its proprietary technology platform XTEN, a proprietary recombinant polypeptide that consists of naturally-occurring hydrophilic amino acids and is biodegradable, for the development of its products. Amunixs product pipeline includes VRS-317, NB1001, NB1002, AMX-342, AMX-182 and AMX-168. The company has developed technology based on XTEN, a hydrophilic polymer comprised of natural amino acids that can be attached to therapeutic peptides, proteins and small molecules. It provides products in the treatment areas include hemophilia, diabetes, short bowel syndrome, NASH, Oncology and lipodystrophy. The company operates through academic, biotechnology and pharmaceutical groups. Amunix is headquartered in Mountain View, California, the US.
Amunix Operating Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
2
List of Tables 3
List of Figures 4
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Amunix Operating Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Versartis Raises US$20 Million In Series D Financing 10
Versartis Secures US$21 Million In Series B Financing Round 11
Diartis Pharma Secures Venture Financing 13
Partnerships 14
Amunix Operating Enters into R&D Agreement with Genentech 14
Roche Extends Agreement with Amunix for XTEN technology 14
Amunix Enters Into Co-Development Agreement With Biogen Idec 15
Licensing Agreements 16
Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 16
Amunix Enters into Licensing Agreement with Naia for GLP-1-XTEN 17
Amunix Enters into Licensing Agreement with Naia for GLP-2-XTEN 18
Amunix Exercises Option for Licensing Agreement with Eli Lilly 19
Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 20
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 21
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 22
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 23
Amunix Operating Inc - Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Corporate Communications 28
Mar 13, 2017: Distinguished Cancer Physician-Scientist Dr. Herbert Pinedo joins Amunix Scientific Advisory Board 28
Feb 13, 2017: Amunix Appoints Fred Hausheer, MD, FACP, as Chief Medical Officer 30
Mar 03, 2016: Harold E. "Barry" Selick, Ph.D. and Walter H. Moos, Ph.D. Join Amunix Board of Directors 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List Of Tables
Amunix Operating Inc, Pharmaceuticals & Healthcare, Key Facts 1
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Amunix Operating Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Amunix Operating Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Versartis Raises US$20 Million In Series D Financing 10
Versartis Secures US$21 Million In Series B Financing Round 11
Diartis Pharma Secures Venture Financing 13
Amunix Operating Enters into R&D Agreement with Genentech 14
Roche Extends Agreement with Amunix for XTEN technology 14
Amunix Enters Into Co-Development Agreement With Biogen Idec 15
Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 16
Amunix Enters into Licensing Agreement with Naia for GLP-1-XTEN 17
Amunix Enters into Licensing Agreement with Naia for GLP-2-XTEN 18
Amunix Exercises Option for Licensing Agreement with Eli Lilly 19
Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 20
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 21
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 22
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 23
Amunix Operating Inc, Key Competitors 25
Amunix Operating Inc, Key Employees 26
List Of Figures
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Amunix Operating Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
RELATED REPORTS
SAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
